Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Receives $10.00 Average PT from Analysts

Shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) have earned an average rating of “Moderate Buy” from the eight analysts that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, four have given a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $10.00.

Several research firms have issued reports on AUTL. Wall Street Zen raised Autolus Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, August 16th. Weiss Ratings upgraded Autolus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 13th. Finally, HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Autolus Therapeutics in a report on Monday, August 3rd.

Autolus Therapeutics Price Performance

NASDAQ AUTL opened at $2.31 on Wednesday. Autolus Therapeutics has a 12 month low of $1.17 and a 12 month high of $2.58. The company has a debt-to-equity ratio of 1.04, a current ratio of 4.89 and a quick ratio of 4.40. The company’s 50 day simple moving average is $1.84 and its 200 day simple moving average is $1.65. The firm has a market capitalization of $614.84 million, a PE ratio of -2.18 and a beta of 2.07.

Autolus Therapeutics (NASDAQ:AUTL) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.06. Autolus Therapeutics had a negative return on equity of 178.66% and a negative net margin of 238.66%.The business had revenue of $45.69 million during the quarter, compared to analyst estimates of $38.56 million. As a group, equities research analysts forecast that Autolus Therapeutics will post -0.75 EPS for the current fiscal year.

Hedge Funds Weigh In On Autolus Therapeutics

Institutional investors have recently bought and sold shares of the stock. Invesco Ltd. raised its stake in shares of Autolus Therapeutics by 53.3% in the 1st quarter. Invesco Ltd. now owns 32,738 shares of the company’s stock valued at $51,000 after acquiring an additional 11,381 shares in the last quarter. Jane Street Group LLC grew its holdings in Autolus Therapeutics by 809.4% during the first quarter. Jane Street Group LLC now owns 102,493 shares of the company’s stock valued at $159,000 after purchasing an additional 91,222 shares during the last quarter. Geode Capital Management LLC grew its holdings in Autolus Therapeutics by 90.5% during the second quarter. Geode Capital Management LLC now owns 164,314 shares of the company’s stock valued at $375,000 after purchasing an additional 78,058 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in shares of Autolus Therapeutics by 41.6% in the second quarter. The Manufacturers Life Insurance Company now owns 38,419 shares of the company’s stock valued at $88,000 after purchasing an additional 11,289 shares during the period. Finally, Bank of America Corp DE raised its position in shares of Autolus Therapeutics by 2,891.7% in the second quarter. Bank of America Corp DE now owns 975,135 shares of the company’s stock valued at $2,223,000 after purchasing an additional 942,540 shares during the period. 72.83% of the stock is currently owned by institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.